| Name | Title | Contact Details |
|---|
Evolent Health supports progressive health care systems lead, build and own the path to value-based care. Headquartered in Arlington, Virginia, we are backed by: The Advisory Board Company (NASDAQ: ABCO), University of Pittsburgh Medical Center Health Plan, and TPG Growth. We integrate the people, processes and technology needed to advance value-based care delivery and innovative payment models.
Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal conditions. Apollo`s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo`s products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the X-Tack™ Endoscopic HeliX Tacking System, and the ORBERA® Intragastric Balloon.
MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
Medical Packaging Corp is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.